- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04169711
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
July 26, 2022 updated by: Arrowhead Pharmaceuticals
A Phase 1b Dose-Finding Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).
Study Overview
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75390
- Research Site
-
Houston, Texas, United States, 77030
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
- Willing to provide written informed consent and to comply with study requirements
- Histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma that has progressed during or after at least two prior therapeutic regimens which must include vascular endothelial growth factor (VEGF)-targeted therapy and checkpoint inhibitor therapy or that has otherwise failed such therapies, is measurable disease per RECIST 1.1 criteria, is biopsy accessible
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Estimated life expectancy of longer than 3 months
- Adequate organ function at screening
Exclusion Criteria:
- History of untreated brain metastasis or leptomeningeal disease or spinal cord compression
- Failure to recover from reversible effects of prior anti-cancer therapy
- Has received systemic therapy or radiation therapy within 2 weeks prior to first dose
- History of solid organ or stem cell transplantation
- Current use of anti-VEGF or mammalian target of rapamycin (mTOR) agents, or chronic immunosuppressive therapy
- Any prior use of hypoxia inducible factor 2 (HIF2) inhibitors within 6 months prior to first dose
- Current use of immune checkpoint inhibitors
- Use of an investigational agent or device within 2 weeks prior to dosing, or current participation in an investigational study
- Known HIV, hepatitis B or hepatitis C
- History of other clinically meaningful disease
- Major surgery within 4 weeks of Screening
- Active malignancy requiring therapy other than ccRCC within 3 years of study entry
Note: Other eligibility criteria may apply per protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARO-HIF2
|
Multiple doses of ARO-HIF2 by intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment
Time Frame: Up to 2 years from first dose
|
Up to 2 years from first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: up to 2 years
|
up to 2 years
|
|
Pharmacokinetics (PK) of ARO-HIF2: Maximum Observed Plasma Concentration (Cmax)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
PK of ARO-HIF2: Time to Maximum Plasma Concentration (Tmax)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to 4 Hours (AUC0-4)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Measurable Concentration at a Time=t, Using a Specified Trapezoidal Rule (AUC0-t)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to Infinity (AUCinf)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
PK of ARO-HIF2: Terminal Elimination Half-Life (t1/2)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
Systemic Clearance Derived From Intravenous Dose/Area Under the Plasma Concentration Versus Time Curve (CL)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
Amount of Drug Excreted in the Urine Over One Dosing Interval Through 4 Hours Post- Dose (Ae, 0-4)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
Renal Clearance Calculated by Ae, 0-4 h/AUC0-4h (CLR)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
Fraction Excreted (or Equivalently the Percent of Dose Excreted) in the Urine, Calculated by 100 X (Ae, 0-4 h/Dose)
Time Frame: Up to Week 2: predose and up to 48 hours postdose
|
Up to Week 2: predose and up to 48 hours postdose
|
|
Overall Response Rate
Time Frame: Baseline until disease progression, up to 2 years
|
Percentage of participants with a best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria.
|
Baseline until disease progression, up to 2 years
|
Duration of Response
Time Frame: Baseline until disease progression, up to 2 years
|
Baseline until disease progression, up to 2 years
|
|
Time to Response
Time Frame: Baseline until disease progression, up to 2 years
|
Baseline until disease progression, up to 2 years
|
|
Progression Free Survival
Time Frame: up to 2 years
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 17, 2020
Primary Completion (ACTUAL)
January 24, 2022
Study Completion (ACTUAL)
July 22, 2022
Study Registration Dates
First Submitted
November 18, 2019
First Submitted That Met QC Criteria
November 18, 2019
First Posted (ACTUAL)
November 20, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 27, 2022
Last Update Submitted That Met QC Criteria
July 26, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AROHIF21001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Cell Carcinoma
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkWithdrawnKidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
-
Queen Mary University of LondonAstraZeneca; Vall d'Hebron Institute of OncologyActive, not recruitingRenal Clear Cell Carcinoma | Renal Papillary Cell CarcinomaUnited Kingdom
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
-
University of WashingtonMerck Sharp & Dohme LLC; Prometheus LaboratoriesTerminatedMetastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
Clinical Trials on ARO-HIF2
-
Arrowhead PharmaceuticalsActive, not recruitingDyslipidemiasUnited States, Australia, Canada, Poland, Netherlands, New Zealand, Hungary
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Arrowhead PharmaceuticalsActive, not recruitingFamilial ChylomicronemiaKorea, Republic of, Canada, Australia, Singapore, Belgium, Spain, Japan, United States, Austria, Germany, Ireland, Oman, Poland, Israel, New Zealand, Argentina, France, Croatia, Mexico, Serbia, Turkey
-
Arrowhead PharmaceuticalsActive, not recruitingHomozygous Familial HypercholesterolemiaAustralia, Canada, United States, South Africa
-
Arrowhead PharmaceuticalsActive, not recruitingMixed DyslipidemiaUnited States, Australia, Canada, New Zealand
-
ARO MedicalUnknownLumbar Disc Prolapse With RadiculopathyDenmark
-
Arrowhead PharmaceuticalsNot yet recruitingSevere Hypertriglyceridemia
-
Arrowhead PharmaceuticalsNot yet recruiting